pharmaphorum

JANUARY 12, 2022

Prospects for Aldeyra’s dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn’t giving up and has new data showing an improvement over Novartis rival therapy Xiidra.

FDA 105

FDA 105

Pharmaceutical Technology

NOVEMBER 7, 2022

Top five pharma companies in the UK’s IT recruitment activity in October 2022. The top five companies, in terms of number of jobs as tracked by GlobalData, have accounted for a combined average growth of 116.38% share in the overall IT recruitment activity of the UK’s pharma industry during October 2022 over September 2022.

52

52

Pharmaceutical Technology

OCTOBER 12, 2022

Top five pharma companies in the UK’s IT recruitment activity in September 2022. The top five companies, in terms of number of jobs as tracked by GlobalData, have accounted for a combined average growth of 200% share in the overall IT recruitment activity of the UK’s pharma industry during September 2022 over August 2022.

52

52

Pharmaceutical Technology

SEPTEMBER 6, 2022

Top five pharma companies in the UK’s IT recruitment activity in August 2022. The top five companies, in terms of number of jobs as tracked by GlobalData, have accounted for a combined average growth of 45.95% share in the overall IT recruitment activity of the UK’s pharma industry during August 2022 over July 2022.

52

52

Pharmaceutical Technology

DECEMBER 5, 2022

Top five pharma companies in the US’s IT recruitment activity in November 2022. The top five companies, in terms of number of jobs as tracked by GlobalData, have accounted for a combined average decline of 9.89% share in the overall IT recruitment activity of the US’s pharma industry during November 2022 over October 2022.

40

40

Pharmaceutical Technology

DECEMBER 5, 2022

Top five pharma companies in the UK’s IT recruitment activity in November 2022. The top five companies, in terms of number of jobs as tracked by GlobalData, have accounted for a combined average decline of 73.14% share in the overall IT recruitment activity of the UK’s pharma industry during November 2022 over October 2022.

40

40

Pharmaceutical Technology

MAY 15, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

PharmaShots

JANUARY 31, 2023

Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. The company bagged its $6.3M LP-310, another lead asset of the company received FDA Type-B Pre-IND guidance recently for Oral Lichen Planus. of Shares: 1.5M

Vaccines 40

Vaccines Immunization FDA 40

Pharmaceutical Technology

JULY 4, 2022

Top five pharma companies in the UK’s IT recruitment activity in June 2022. The top five companies, in terms of number of jobs as tracked by GlobalData, have accounted for a combined average decline of 11.54% share in the overall IT recruitment activity of the UK’s pharma industry during June 2022 over May 2022.

40

40

pharmaphorum

MAY 13, 2022

Shares in the company were down nearly 15% in the wake of the announcement. Since then, Cosentyx has been joined by other IL-17 inhibitors including Eli Lilly’s Taltz (ixekizumab) and Bausch Health’s Siliq/Kyntheum (brodalumab), giving UCB a mountain to climb to differentiate its drug.

FDA 52

FDA 52

pharmaphorum

APRIL 28, 2021

The decision – announced in the company’s first-quarter results statement – comes shortly after Lilly reported positive phase 3 results with mirikizumab in ulcerative colitis.

52

52

pharmaphorum

SEPTEMBER 15, 2022

More threatening perhaps to Aldeyra’s programme is Bausch Health and Novaliq’s NOV03 (perfluorohexyloctane), which has already been filed for approval after positive results from a second phase 3 trials were reported earlier this year.

FDA 52

FDA Packaging 52

The Checkup by Singlecare

SEPTEMBER 14, 2023

The manufacturer advertises that 86% of people with health insurance have access to Trulance, but insurance coverage may vary. Some health insurance plans do not cover Trulance. Talk to your insurance company before filling a Trulance prescription to make sure. The earliest a generic may be available is 2032.

Insurance 52

Insurance Insurance Coverage FDA 52

Pharmaceutical Technology

SEPTEMBER 26, 2022

Health Canada has granted approval for Bausch Health and Glenmark Pharmaceuticals subsidiary Glenmark Specialty’s Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) as a symptomatic therapy for moderate to severe seasonal allergic rhinitis (SAR).

52

52

PharmaShots

JANUARY 23, 2023

Smriti: Highlight the key findings obtained from the P-III clinical trial evaluating VTAMA cream based on which your company received the approval. Prior to joining Dermavant, Stacey was the Vice President of Marketing for Ortho Dermatologics, a Division of Bausch Health Inc.,

FDA 40

FDA Labelling Immunization 40

pharmaphorum

SEPTEMBER 4, 2020

Leela Barham asks why companies may choose to not submit their drugs to NICE and keep them off routine commissioning – a trend that appears to be on the rise. Yet it is clear that companies choose not to submit to NICE, that raises questions; why and so what? Bausch & Lomb (2). Rise in non-submissions.

64

64

PharmaShots

JUNE 21, 2023

with schizophrenia. The results showed that the patients treated with Uzedy achieved a ~80% reduction in risk of schizophrenia relapse over PBO Uzedy, the first SC, long-acting formulation of risperidone that has been developed using SteadyTeq (copolymer technology) to MedinCell that controls the steady release of risperidone 2. vs -2.3mL/min/1.73

FDA 40

FDA Hospitals 40